Live Chat Software

Exclusive Content

Managed Access Programs: Reaching Patients in Need

Managed Access Programs: Reaching Patients in Need

Navigating the MAP: Durbin offers the regulatory expertise, and vast distribution networks, to get the most out of a Managed Access Program for both patients and Biotech/ Pharmaceutical companies. Read more here.
Five minutes with Vee Mapunde on: the growing influence of patient advocacy groups in Early Access Programmes

Five minutes with Vee Mapunde on: the growing influence of patient advocacy groups in Early Access Programmes

We had a chat with Vee Mapunde, Associate Consumer Lead at the National Cancer Research Institute (NCRI) on the role of patient advocacy groups in the Early Access Prorammes landscape, their missions and the tools they have to fulfill them, ahead of the Early and Managed Access Programmes conference (24th-26th October 20170. The power is now shifting towards the patients, so what impact does this have on patient advocacy groups?

Three tips to ensure an ethical and sustainable Early Access Programme

Three tips to ensure an ethical and sustainable Early Access Programme

Early and Managed Access Programmes can prolong the life of patients who have a life-threatening illness or a chronic or rare condition, by providing them access to investigational drugs. Their investigative nature does mean that ethical challenges often arise during their process. With this in mind, Pharma IQ have worked with industry and compiled three 'top tips' to ensure an ethical and sustainable Early Access Programme.